MPLT Key Statistics, Chart & Performance
The current stock price of MPLT is 18.8 USD. In the past month the price increased by 6.33%.
MPLT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MPLT.
MPLT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MPLT. MPLT has a great financial health rating, but its profitability evaluates not so good.
MPLT Financial Highlights
Over the last trailing twelve months MPLT reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS decreased by -39.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.27% | ||
| ROE | -203.52% | ||
| Debt/Equity | 0 |
MPLT Forecast & Estimates
10 analysts have analysed MPLT and the average price target is 31.62 USD. This implies a price increase of 68.19% is expected in the next year compared to the current price of 18.8.
MPLT Ownership
About MPLT
Company Profile
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California and currently employs 109 full-time employees. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.
Company Info
MAPLIGHT THERAPEUTICS INC
800 Chesapeake Drive
Redwood City CALIFORNIA US
Employees: 109
Phone: 16508394360
MAPLIGHT THERAPEUTICS INC / MPLT FAQ
What does MPLT do?
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California and currently employs 109 full-time employees. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.
Can you provide the latest stock price for MAPLIGHT THERAPEUTICS INC?
The current stock price of MPLT is 18.8 USD. The price decreased by -1.83% in the last trading session.
Does MAPLIGHT THERAPEUTICS INC pay dividends?
MPLT does not pay a dividend.
How is the ChartMill rating for MAPLIGHT THERAPEUTICS INC?
MPLT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of MPLT stock?
MAPLIGHT THERAPEUTICS INC (MPLT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for MAPLIGHT THERAPEUTICS INC?
MAPLIGHT THERAPEUTICS INC (MPLT) will report earnings on 2026-03-02.